Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies

BACKGROUND: A previous phase II trial in patients with chemorefractory metastatic colorectal cancer demonstrated a 63 % disease control rate with a combination of bevacizumab and sorafenib. This phase I trial sought to determine the maximum tolerable dose (MTD) of bevacizumab and sorafenib combined...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Invest New Drugs
Main Authors: Hubbard, Joleen M., Kim, George, Borad, Mitesh J., Johnson, Elizabeth, Qin, Rui, Lensing, Janet, Puttabasavaiah, Suneetha, Wright, John, Erlichman, Charles, Grothey, Axel
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4729450/
https://ncbi.nlm.nih.gov/pubmed/26581401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0308-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares